Pharmac extending consultation period on the proposed changes to diabetes medicine criteria
Source: PHARMAC Pharmac is extending the consultation period on proposed changes to access criteria for type 2 diabetes medicines. In May, Pharmac released a proposal to amend the Special Authority criteria for empagliflozin, liraglutide, and dulaglutide. The consultation has received a significant amount of feedback, reflecting how important access to these treatments is for people…